Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:03 PM
Ignite Modification Date:
2025-12-24 @ 5:03 PM
NCT ID:
NCT07131150
Eligibility Criteria:
Inclusion Criteria:
* 1\. Voluntarily sign the written informed consent (ICF) and agree to complete the trial according to the protocol requirements;
* 2\. ≥ 18 and ≤ 80 years old when signing the ICF , regardless of gender;
* 3\. Diagnostic Confirmation of IPF;
* 4\. ≥ 50% and ≤ 90% at screening ; DLCO% ≥ 30% and ≤ 90% (corrected for hemoglobin \[Hb\]);
* 5\. received nintedanib or pirfenidone treatment for at least 8 weeks before screening and do not plan to start or restart anti-fibrotic treatment; or patients who have received stable nintedanib or pirfenidone treatment for at least 8 weeks before screening and do not receive combination therapy of nintedanib and pirfenidone ;
* 6\. 2 ≥ 60 mmHg at screening ; able to complete the 6- minute walk test ( 6MWT ) and walk distance \> 150 m;
* 7\. are willing to use at least one effective contraceptive method for contraception during the study .
Exclusion Criteria:
* 1\. Other lung diseases within 6 months before screening, including chronic obstructive pulmonary disease (forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) after using bronchodilator \< 0.70), emphysema (emphysema occupies ≥ 50% of the entire HRCT according to the central review of HRCT, or the degree of emphysema is greater than the degree of fibrosis), pulmonary hypertension ≥ 50 mmHg indicated by echocardiography , active tuberculosis, pulmonary embolism, uncontrolled asthma, pneumothorax, pneumoconiosis, bronchiolitis obliterans or other active lung diseases;
* 2\. In addition to IPF, there are other types of interstitial lung disease (ILD), including ILD with known causes (such as family or occupational environmental exposure, connective tissue disease and drug toxicity, etc.), granulomatous ILD (such as sarcoidosis), and other rare ILD (such as alveolar proteinosis, pulmonary amyloidosis, etc.); among them, for the exclusion of connective tissue disease-related interstitial lung disease ( CTD-ILD), relevant examinations within 12 months before screening were accepted;
* 3\. Patients who are in the acute exacerbation stage of IPF at the time of screening, or who have AE-IPF within 3 months before screening (determined by the investigator); AE-IPF is defined as: IPF patients who have a significant acute deterioration of respiratory function in a short period of time, mainly characterized by the new appearance of diffuse ground-glass shadows and/or consolidation shadows in both lungs on the original UIP background on chest HRCT;
* 4\. Patients with lung infection or other serious infection requiring intravenous antibiotic treatment within 4 weeks before screening;
* 5\. Patients with a history or evidence of major cardiovascular disease within 6 months before screening, including but not limited to: myocardial infarction, coronary angioplasty or bypass surgery, heart valve repair, II or III degree atrioventricular block, malignant arrhythmia ( such as ventricular tachycardia, frequent supraventricular tachycardia, atrial fibrillation, atrial flutter, etc. ), unstable angina, transient ischemic attack, cerebrovascular accident, congestive heart failure with a heart function grade of III or IV of the New York Heart Association (NYHA) , etc.; or left ventricular ejection fraction (LVEF) \<50% at screening;
* 6\. Patients with a history of tumor (except for patients with cured basal cell carcinoma of the skin, squamous cell carcinoma in situ of the skin, or carcinoma in situ of the cervix), or patients whose tumor marker examinations are determined by the investigator to be clinically significant and may affect safety assessments;
* 7\. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 × upper limit of normal (ULN), or total bilirubin (TBIL) \>1.5 × ULN at screening;
* 8\. Estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73m² at screening;
* 9\. Patients who are positive for hepatitis B surface antigen (HBsAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) ≥ the lower limit of the detection value during screening, or who are positive for hepatitis C virus (HCV) antibody and hepatitis C virus ribonucleic acid (HCV-RNA) ≥ the lower limit of the detection value, or who are positive for human immunodeficiency virus (HIV) antibody, or who are positive for Treponema pallidum antibody (Those who are positive for Treponema pallidum antibody need to undergo non-specific syphilis antibody test and the researchers will determine whether they can participate in the trial);
* 10\. Blood pressure is still not controlled after antihypertensive drug treatment within 3 months before screening, and blood pressure during the screening period is ≥ 160/100 mmHg;
* 11\. Patients planning to receive lung transplantation or with a history of solid organ transplantation;
* 12\. Those who have undergone lung resection; or those who have undergone major surgery (including lung surgery) or unhealed wounds (except for diagnostic surgery or when the investigator determines that the subject has fully recovered from the surgery) within 4 weeks before screening, or those who are planning to undergo major surgery;
* 13\. 20 mg/ d (or other glucocorticoids of equivalent dose) within 28 days before screening ;
* 14\. Use of cytotoxic drugs (such as chloramphenicol, azathioprine , cyclophosphamide, methotrexate ) or pulmonary hypertension drugs (such as endothelin receptor antagonists \[such as bosentan, ambrisentan, macitentan\], PDE5 inhibitors \[such as sildenafil, tadalafil, vardenafil \]) within 4 weeks or 5 half -lives before screening (whichever is longer) ;
* 15\. Use of drugs that may cause pulmonary fibrosis within 6 months before screening, such as amiodarone, bleomycin, etc.;
* 16\. Patients who are known or suspected to be allergic to the active or inactive ingredients of the investigational drug (such as dimethyl sulfoxide \[DMSO\], human serum albumin \[HSA\], dextran, and compound electrolytes) ;
* 17\. Those with a history of drug abuse or other serious mental illness, who may increase the risk of participating in the study or interfere with the study treatment and research results as determined by the researchers;
* 18\. Participants who have participated in any other clinical trials within 3 months before screening (except patients who have not received trial drugs); or participated in mesenchymal stem cell clinical trials within 2 years before screening; or received other types of stem cells before screening;
* 19\. Other situations that the researcher considers unsuitable for participation in this trial.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT07131150
Study Brief:
Protocol Section:
NCT07131150